Feedback
Settings

Settings

Goto Application

123,858 results
Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12,386
1.WO/2020/185746NOVEL APPLICATION FOR INHIBITORS OF CAMP EFFLUX IN BODY CARE
WO - 17.09.2020
Int.Class A61K 8/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
 Appl.No PCT/US2020/021838 Applicant STC. UNM Inventor PEREZ, Dominique, Renee
The present invention is directed to previously identified inhibitors ofcAMP efflux (ICE) and their use in feaiing/niasking body odor, inhibiting, reducing and/or eliminating hyperhidrosis (excessive sweating), tanning skin or protecting skin before and/or after exposure to the sun as well as.for treating certain skin conditions, in one embodiment, the invention provides a method for inhibiting body odor, a condition that is characterized by an unpleasant odor from the products of the microbial sweat degradation. By inhibiting the efflux of the precursor compounds that are degraded, novel compounds are- capable of preventing unwanted odors. Deodorant compositions that employ this new approach for the control of bodily odor are provided, ICE compounds can also be used as. components, of cosmetic formulations including tanning and after-sun formulations, formulations for skin conditions as described herein and other cosmetic formulations.
2.WO/2020/186124MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
WO - 17.09.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/US2020/022519 Applicant THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK Inventor JU, Jingfang
The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
3.WO/2020/182803DALCETRAPIB IN THE TREATMENT OF SICKLE CELL TRAIT
WO - 17.09.2020
Int.Class A61K 31/167
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
 Appl.No PCT/EP2020/056331 Applicant HARTIS-PHARMA SA Inventor NIESOR, Joseph Eric
The present invention is related to dalcetrapib or dalcetrapib-thiol, or a combination thereof for use in the prevention and/or treatment of disorders characterized by inefficient transport and delivery of oxygen to peripheral tissues. The invention in particular relates to pharmaceutical formulations, regimens, methods of treatment and uses thereof.
4.WO/2020/185092USE OF VITAMIN K IN COMBINATION WITH ANTICOAGULANTS
WO - 17.09.2020
Int.Class A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
 Appl.No PCT/NO2020/050066 Applicant KAYDENCE PHARMA AS Inventor VAN GORP, Rick
A method of treating or preventing a condition characterized by unacceptable blood clotting and/or an increased risk thereof, the method including administering to a subject in need thereof a combination of vitamin K2 and at least one anticoagulant, the at least one anticoagulant having a first anticoagulant configured to inhibit free Factor Xa and/or Factor Xa bound in a prothrombinase complex of the subject.
5.WO/2020/185532METHODS OF TREATING CANCER WITH AN FGFR INHIBITOR
WO - 17.09.2020
Int.Class A61K 31/5375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
 Appl.No PCT/US2020/021313 Applicant INCYTE CORPORATION Inventor JI, Tao
This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
6.WO/2020/183011HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER
WO - 17.09.2020
Int.Class A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
 Appl.No PCT/EP2020/056957 Applicant INSTITUT CURIE Inventor ROMAN ROMAN, Sergio
The present invention deals with a 5 -hydroxytryptamine receptor 1D (5-HTR1D) inhibitor and with a combination of a 5-HTR1D inhibitor and at least one inhibitor of 5 -hydroxytryptamine receptor 1B (5-HTR1B) for use in the prevention and/or treatment of cancer in a subject in need thereof. According to the invention the cancer may be selected from the group comprising breast cancer, liver cancer, lung cancer, brain cancer, mesothelioma, head and neck squamous cell carcinoma, kidney cancer, gastric cancer and cervix cancer.
7.WO/2020/183021LANABECESTAT FOR WEIGHT LOSS
WO - 17.09.2020
Int.Class A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
 Appl.No PCT/EP2020/056994 Applicant ASTRAZENECA AB Inventor SHERING, Craig
The present application relates to affecting weight loss comprising administereing a therapeutically effective amount of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1- yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine, or a pharmaceutically acceptable salt thereof (e.g., the camsylate salt of (1r,1'R,4R)- 4-methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''- imidazol]-4''-amine).
8.WO/2020/184271OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION
WO - 17.09.2020
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/JP2020/008812 Applicant NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY Inventor MIYAKO, Eijiro
The present invention provides an optically heat-generating composite material which is represented by formula (I) CNM-(Y1-R)n1 (wherein CNM represents a carbon nanomaterial; Y1 represents a divalent linking group; R represents a group derived from a fluorescent substance or a pigment; and n1 represents an integer of 1 or more).
9.WO/2020/185041HYDROGEL INCLUDING SEROTONIN-MODIFIED HYALURONIC ACID AND USE THEREOF
WO - 17.09.2020
Int.Class A61L 24/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
24Surgical adhesives or cements; Adhesives for colostomy devices
 Appl.No PCT/KR2020/003549 Applicant INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Inventor CHO, Seung Woo
The present invention relates to a hydrogel including serotonin-modified hyaluronic acid, a use thereof, and a method for manufacturing same.
10.WO/2020/184700NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
WO - 17.09.2020
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/JP2020/011018 Applicant RENA THERAPEUTICS INC. Inventor KIZAWA Hideki
Provided are a nucleic acid complex and a method for lowering the expression of IHH gene mRNA and protein in an animal.　The nucleic acid complex for lowering the expression of IHH gene mRNA and protein acts as a specific inhibitor of the IHH gene and is therefore useful in elucidating IHH gene function. A specific inhibitor of the IHH gene is also useful in treating, preventing, improving, or slowing the advance of fibrosis and fibrotic disease. This nucleic acid complex specifically inhibits expression of the IHH gene and is therefore useful in patients who require treatment, prevention, improvement, or slowing of the advance of fibrosis and fibrotic disease.
# -